Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2352W HIGH $15.50
Volume
22.21 K
Value Traded
37.11 K
Short % Float
0.14%
-4.19%Week
-18.37%1 Month
-53.89%3 Month
-49.13%6 Month
-70.14%5 Year
-70.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.24 M
EPS (TTM)
-2.67
P/E Ratio
-
Ent. Value
5.27 M
Total Shares
7.02 M
Float Shares
4.84 M
Insiders
31.06%
Institutions
16.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RGNT Catalyst Timeline
Dated clinical, regulatory and corporate events for Regentis Biomaterials Ltd.
Past FDA Catalysts and PDUFA Decisions
How RGNT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Regentis Biomaterials Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every RGNT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GelrinC | knee cartilage repair | Phase 3 | 2026-01-20 | 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage; MRI findings revealed progressive improvement in tissue organization over time; By 24 months, the repaired tissue exhibited a layered architecture comparable to native hyaline cartilageRead More | Regentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted MethodRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Alpert Susan PHD MDDirector | Grant/Award | 24,826 24,826 held | $0.00 | 07/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RGNT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RGNT for Q2 2026. | ||||
RGNT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RGNT ranks across every disease it competes in
Competitive Position is a premium feature
See how RGNT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRGNT News
RGNT▼ -5.9%today
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
Regentis Biomaterials will present at the 2026 ThinkEquity Conference on October 15, highlighting its GelrinC technology and ongoing FDA pivotal Phase III trial. CEO Ehud Geller and CFO Ori Gon will discuss recent developments and the product's CE Mark approval in Europe. GelrinC aims to address knee cartilage injuries with a unique hydrogel implant.
Read more →RGNTRegentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Regentis Biomaterials reported its financial results for the first half of 2026, highlighting advancements in the GelrinC pivotal trial with 43 patients treated. The company expects to complete enrollment by year-end 2026 and is enhancing European commercialization efforts. A recent $6.5 million private placement has strengthened its financial position.
Read more →RGNT▼ -22.1%on this news
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement HERZLIYA, IL
Regentis Biomaterials Ltd. has announced a private placement aimed at raising $6.5 million through the issuance of ordinary shares and warrants. The company plans to use the proceeds to support its pivotal clinical trial for GelrinC and advance regulatory submissions, including activities for FDA approval. GelrinC is an innovative hydrogel for knee cartilage repair that has already received CE Mark approval in the EU. The placement is expected to close around June 23, 2026, pending customary closing conditions.
Read more →RGNTRegentis to Commence European Surgeon Training GelrinC in Knee Cartilage Repair as Commercial Launch
Regentis Biomaterials Ltd. is preparing to commence European surgeon training for GelrinC, its innovative cell-free hydrogel implant for knee cartilage repair, having received CE Mark approval. The training aims to equip orthopedic surgeons with hands-on experience using GelrinC, which is designed to streamline the 10-minute implantation process. This initiative signifies a critical step towards commercialization in a competitive $3 billion market, where traditional solutions have been prevalent. Clinical data suggest GelrinC provides enhanced recovery outcomes, and Regentis aims to foster confidence and support among surgeons through a network of Centers of Excellence across Europe.
Read more →RGNTNOTICE OF AN ANNUAL GENERAL MEETING OF THE SHAREHOLDERS TO BE HELD ON THURSDAY, JULY 2, 2026 To the shareholders of Regentis Biomaterials Ltd.: Notice is hereby given that an Annual General Meeting (the " Meeting ") of t
Regentis Biomaterials Ltd. has scheduled its Annual General Meeting for July 2, 2026, in Tel Aviv, Israel. The meeting will address several key agenda items, including the re-elections of directors, approval of options grants, and the adoption of the company's Compensation Policy. Shareholders as of June 9, 2026, will be entitled to vote and participate in discussions concerning financial statements and other business matters. The Board of Directors advises shareholders to vote in favor of all proposed items.
Read more →RGNT▲ +8.1%on this news
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
Regentis Biomaterials reported its 2025 financial results and provided a business update, announcing $7.4 million in cash to support site expansion and patient enrollment for its pivotal Phase III trial of GelrinC. GelrinC is already approved in Europe and is slated for rollout in 2026, aiming to be the first ready-to-use, off-the-shelf product in the U.S. for knee cartilage repair. Despite these advancements, the company noted a going concern qualification in its audit report, emphasizing the importance of upcoming trial outcomes and financial health.
Read more →RGNT▼ -10.5%on this news
Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs
Regentis Biomaterials has announced the expansion of its European clinical site network, strategically increasing its presence in key markets like Italy and Eastern Europe. This move supports its ongoing pivotal Phase III clinical trials in conjunction with the commercial launch of GelrinC, which has already received CE Mark approval for knee cartilage repair. The expansion aims to deepen engagement with orthopedic surgeons and facilitate broader clinical adoption, enhancing Regentis' commercial strategy ahead of its targeted launch in 2026.
Read more →RGNT▼ -17.1%on this news
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
Regentis Biomaterials has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. His experience is expected to aid the company's transition towards commercialization of GelrinC, a hydrogel implant for knee cartilage repair. GelrinC has received CE Mark approval in Europe and is currently undergoing a pivotal Phase III trial in the U.S.
Read more →RGNTRegentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
Regentis Biomaterials has expanded its U.S. clinical site network for the pivotal Phase III study of GelrinC, a hydrogel for knee cartilage repair. The addition of leading orthopedic centers aims to accelerate patient enrollment and enhance clinical data generation. GelrinC is already approved in the EU and targets a significant U.S. market.
Read more →RGNTRegentis’ GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
Regentis Biomaterials has announced promising long-term results from its GelrinC treatment for knee cartilage repair. MRI data shows that patients treated with GelrinC exhibit cartilage structures resembling healthy native tissue, indicating true biological regeneration. This innovative hydrogel limits fibrotic tissue overgrowth and supports natural joint biomechanics, enhancing the potential for durable joint function.
Read more →RGNTRegentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Regentis Biomaterials announced that their product GelrinC has shown long-term durability in cartilage repair using MOCART, a quantitative evaluation method published in a peer-reviewed journal. The results indicate that two years post-treatment, cartilage regeneration closely resembles healthy cartilage, thus positioning GelrinC as a leader in cartilage repair solutions. The Phase II clinical trial was conducted with oversight from Vienna University and highlights GelrinC's competitive edge against other treatment options. Currently, GelrinC is undergoing a pivotal Phase III trial in the U.S., with enrollment surpassing 50%.
Read more →RGNTRegentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
Regentis Biomaterials announced the issuance of a new U.S. patent for its regenerative cartilage repair product, GelrinC. This patent protects the ready-to-use liquid formulation that improves surgical efficiency by enabling a quicker procedure. GelrinC, which has already gained CE Mark approval in the EU, is currently undergoing a pivotal FDA trial and has surpassed 50% enrollment. The product offers a promising solution for knee cartilage repair, backed by a robust intellectual property portfolio.
Read more →RGNTRegentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Regentis Biomaterials Ltd. has successfully closed its initial public offering, raising $10 million by selling 1,250,000 ordinary shares at $8.00 each. The shares commenced trading on the NYSE American under the ticker RGNT. The company plans to utilize the proceeds for development activities, including a pivotal trial for its lead product, GelrinC.
Read more →RGNTRegentis Biomaterials Ltd. Announces Pricing of Initial Public Offering
Regentis Biomaterials Ltd. has announced the pricing of its initial public offering, setting the price at $8.00 per share for a total of $10 million in gross proceeds. The company will utilize the funds primarily for development activities related to its lead product, GelrinC, which is aimed at treating knee cartilage injuries. Ordinary shares are expected to begin trading on the NYSE American under the ticker RGNT on December 4, 2025. The offering also allows underwriters a 45-day option to purchase additional shares for over-allotments.
Read more →About Regentis Biomaterials Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next RGNT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime